Roche and Schering-Plough Corporation (NYSE: SGP) today announced that they have entered into a cross licensing agreement that settles all patent disputes relative to the two companies’ peginterferon products. Each party will also license to the other its patents applicable to peginterferon as more
To use all functions of this page, please activate cookies in your browser.